

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 20, 2020

**MICROBOT MEDICAL INC.**  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

000-19871  
(Commission  
File Number)

94-3078125  
(IRS Employer  
Identification No.)

25 Recreation Park Drive, Unit 108  
Hingham, Massachusetts 02043  
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Stock, \$0.01 par value	MBOT	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

On August 20, 2020, Microbot Medical Inc. (the “Company”) issued a press release announcing that Harel Gadot, the Company’s CEO, President and Chairman, will host a webcast on Wednesday, August 26, 2020, at 11:00 a.m., Eastern time. Mr. Gadot will share the Company’s view on the surgical robotic market, the results of its recently announced feasibility animal study with respect to the Company’s LIBERTY™ Robotic System, as well as other recent achievements.

To participate on the webinar, participants must register in advance at: [https://zoom.us/webinar/register/WN\\_5JfsfM-aR4WVKdJncgGbvW](https://zoom.us/webinar/register/WN_5JfsfM-aR4WVKdJncgGbvW). After registering, participants will receive a confirmation email containing information about joining the webinar.

The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K are incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).

**Item 9.01. Financial Statements and Exhibits.****(d) Exhibits**

<b>Exhibit Number</b>	<b>Description</b>
99.1	<a href="#">Press Release</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**MICROBOT MEDICAL INC.**

By: /s/ Harel Gadot

Name: Harel Gadot

Title: Chief Executive Officer, President and Chairman

Date: August 20, 2020

---



## **Microbot Medical Schedules Virtual Meeting to Address Increased Interest Following its Recent Announcement**

*Webinar to be Held on Wednesday August 26<sup>th</sup> at 11am ET*

**HINGHAM, Mass., August 19, 2020** – Following its participation at the Needham Virtual Med Tech & Diagnostic conference, as well as the overwhelming interest generated since its recent announcement which included the outcome of a feasibility animal study with respect to the LIBERTY™ Robotic System, Microbot Medical Inc. (Nasdaq: MBOT) will host a webinar on Wednesday, August 26, 2020 at 11:00am ET. Harel Gadot, the Company's CEO, President and Chairman, will share the Company's view on the surgical robotic market, the results of the feasibility animal study, as well as other recent achievements. Additionally, members of the Company's management team, including Dr. Eyal Morag, Chief Medical Officer, Simon Sharon, Chief Technology Officer and Eran Cohen, Senior Director of Business Development, will be available for a question and answer session.

To participate on the webinar, please register in advance at: [https://zoom.us/webinar/register/WN\\_5JfsfM-aR4WVKdJncgGbvW](https://zoom.us/webinar/register/WN_5JfsfM-aR4WVKdJncgGbvW). After registering, participants will receive a confirmation email containing information about joining the webinar.

The LIBERTY™ Robotic System, which the Company believes to be the first fully disposable surgical robotic system, has met all of its end points with no intraoperative adverse events. This supports the Company's vision of democratizing endoluminal procedures while enhancing clinical and economical outcomes. The LIBERTY™ Robotic System has the potential to allow physicians to conduct catheter-based procedure from outside the catheterization laboratory (cath-lab), avoiding radiation exposure, physical strain and the risk of cross contamination. The study was performed by two leading physicians in the neuro vascular and peripheral vascular intervention spaces, and the results demonstrated robust navigation capabilities, intuitive usability and accurate deployment of embolic agents, most of which was conducted remotely from the cath-lab's control room.

### **About Microbot Medical**

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at <http://www.microbotmedical.com>.

---

**Safe Harbor**

Statements pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY™, the outcome of its studies to evaluate the SCS and other existing and future technologies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC) and in the prospectus supplement related to the registered direct offering to be filed with the SEC, which are or will be available on the SEC’s web site at [www.sec.gov](http://www.sec.gov). Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

**Investor Contact:**

Michael Polyviou  
EVC Group  
[mpolyviou@evcgroup.com](mailto:mpolyviou@evcgroup.com)  
732-933-2754

---